Ventripoint to Exhibit the VMS+ 3.0 System at American College of Cardiology Annual Conference and Grant of Options
Toronto, Ontario, February 27, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it will be exhibiting at the American College of Cardiology’s 68th Annual Scientific Session & Expo to showcase its next-generation VMS+ 3.0 system (http://2019.acccongress.com).
ACC’s Annual Scientific Session, taking place March 16 – 18, 2019 in New Orleans, is the global marketplace for cardiovascular innovation with over 19,000 attendees from 120 countries. Ventripoint will be exhibiting in booth #2426, performing live hands-on demonstrations of the VMS+ 3.0 system with a clinician.
“We are looking forward to performing live scanning of our next-generation VMS+ 3.0 system in our booth. This will provide an opportunity for hands-on use by leading cardiologists from around the world,” notes Dave McPhedran, Head of Global Sales at Ventripoint Diagnostics.
The VMS+ 3.0 system is designed to use Artificial Intelligence (AI) to provide a streamlined approach for volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo images. A new interactive guided workflow has been embedded in the VMS+ system to highlight view capture and point placement on each view to increase efficiency and ease of use while performing imaging and analysis. The system uses a new patent-pending position sensor, which allows the patient to re-position during the imaging portion of the exam. The compact and portable system can be set-up within minutes.
The VMS+ 3.0 system is not commercially available for sale. For investigational use only.
In other news, on February 5, 2019 the Board of Directors granted a total of 625,000 common share stock options at an exercise price of $0.16 per share. Three Officers of the Company were granted a total of 175,000 options and four independent directors were granted a total of 200,000 options, all of which have a maturity date of five years from the date of issuance, and vest over either three years or one year, respectively. The remaining options were granted to employees and consultants.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.